Community news|27/07/18

Overview of new forms of employment – 2018 update

Home > The news of EUROGIP and occupational risks in Europe > Overview of new forms of employment – 2018 update

Across Europe, new forms of employment are emerging that differ significantly from traditional employment. Some of these forms of employment transform the relationship between employer and employee while others change work organisation and work patterns. They often involve locations other than the usual employer’s premises and/or extensive use of information and communications technology.

This new report published by Eurofound to update the 2015 overview identifies nine forms of employment that are either new or have become increasingly important in Europe since the year 2000: Strategic employee sharing, Job sharing, Interim management , Casual work, ICT-based mobile work, Voucher-based work, Portfolio work, Platform work, Collaborative self-employment. All of them are aimed at increasing flexibility for employers and/or employees.

Some may benefit employers and employees equally, but in a few cases there are concerns regarding their impact on working conditions and the labour market. The report highlights the need for awareness of potential problems and of safety nets for workers.

To find out more 

Discover other news

Community news

24/01/25

Improving working conditions in social services: 10 recommendations

A new report from the partners in the European IWorCon project, which aims to improve working conditions in the social sector (social and medico-social in France), enhance its attractiveness and strengthen the capacity of employers' organisations, sets out ten recommendations to this end.

Abroad

21/01/25

GERMANY: Three new occupational diseases recognised

Under a new regulation adopted on 11 December 2024, three new diseases have been added to the list of occupational diseases and may be recognised as such under certain conditions. These are damage to the shoulder rotator cuff, gonarthrosis and chronic obstructive pulmonary disease.